Stock Groups

Novavax completes filing process for COVID-19 vaccine’s WHO emergency listing -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: This illustration, taken on October 30, 2020 by Dado Ruvic/File Photo shows a woman holding a small bottle labeled “Coronavirus CoVID-19 Vaccine”. She also holds a Novavax logo and a medical needle in her hand. REUTERS/Dado Ruvic/File Photo

(Reuters) – Vaccine developer Novavax (NASDAQ.) Inc has announced that on Thursday, it submitted a request for the emergency use listing with the World Health Organization of COVID-19 its vaccine candidate.

It stated that it had submitted to WHO all necessary modules for the regulatory review of NVXCoV2373, the protein-based COVID-19 vaccilla.

Novavax, which had stated that its vaccine is more effective than 90% in the late-stage U.S. clinical trial in June, was correct.

It comes just days after receiving its emergency use authorization form Indonesia. In a statement, the company said that they expected Indian and Philippine regulators to approve the COVID-19 vaccination within weeks.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]